, was conducted for recipients aged 1-64 years. Recipients with an AOE medical claim (index diagnosis) followed within five days by a claim for Ciprodex or Cortisporin were identified. Any recipients with dual therapy (defined as greater than one antibiotic or otic agent), concomitant infection, AOE diagnosis within 30 days prior to index diagnosis, or other diagnosis warranting antibiotic therapy within 30 days post index claim were excluded. Each recipient's medical and pharmacy claims for 30 days after the index diagnosis were identified and evaluated for treatment failure. Treatment failure was defined as presence of an additional prescription claim for an antibiotic (oral or otic) or an antibiotic-steroid combination with or without another medical AOE claim. The two drug cohorts (Ciprodex and Cortisporin) were matched using the greedy match technique. Effectiveness, defined as the proportion of failure patients in each cohort, was analyzed using the binomial proportion test. RESULTS: The population consisted predominately of females (55.66%), Caucasians (63.49%), and recipients from the New Orleans region (34.02%). Forty-eight percent of the prescription claims were written by pediatricians. Each matched cohort had 901 recipients with average age 10.01 (SD = 6.50) years (Ciprodex), and 10.45 (SD = 7.27) years (Cortisporin). Before propensity score matching, the respective failure rates for Cortisporin and Ciprodex were 7.47% and 4.69% (p = 0.0009). Within the matched cohorts, respective failure rates for Cortisporin and Ciprodex were 6.88% and 4.77% (p = 0.056). CONCLUSION: In the Louisiana Medicaid population, Cortisporin had a higher failure rate than Ciprodex for AOE; after propensity score matching the difference approached statistical significance at the 0.05 alpha level.
PSS4 THE RCT EVIDENCE OF COMPARATIVE EFFECTIVENESS AND SAFETY OF TOPICAL GLAUCOMA MEDICATION
Lee CW 1 , Buckley F 2 , Costello S 2 , Stoddart SD 2 , Kelly S 1 1 Pfizer, Tadworth, Surrey, UK, 2 Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK OBJECTIVE: To classify published randomised controlled trials (RCTs) regarding the comparative efficacy and safety of topical glaucoma treatment to identify where the evidence lies and the gaps for future research. METHODS: A systematic search of MEDLINE, EMBASE, Cochrane Central and conference proceedings for RCTs recruiting adults with primary open-angle glaucoma (POAG) and/or ocular hypertension (OH) receiving any topical medication or placebo. After double-data entry, the characteristics were analysed with a focus on prostaglandincontaining trials. RESULTS: We identified 510 RCTs. Mean study duration was 15.2 weeks (SD 19.9), with 78% of studies lasting less than three months. Grouping of studies by duration and treatment showed that short-term efficacy was available for all treatments, but RCT evidence of longer-term safety (>12 months) was confined to latanoprost (three trials) and timolol maleate (two trials) in the monotherapy group and dorzolamide and timolol in fixed combination (one trial). The majority of the study population (79.6%) was Caucasian. The data on co-morbidity was sparse. Of prostaglandins, only latanoprost reported hypertension as a sub-group. Latanoprost monotherapy and latanoprost/timolol fixed combination therapy had been compared with the broadest range of alternative therapies. Latanoprost alone had been compared with all other classes of treatments. CONCLUSION: There are extensive RCT data available for glaucoma treatment. Latanoprost has the most RCTs and is the only prostaglandin analogue with RCTs over 12 months. Other research methodologies (i.e. observational studies) have to be considered alongside RCTs to address important clinical issues like long-term safety and disease progression. There is a lack of RCT evidence to explore differential treatmenteffects among subgroups.
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PSS5 MEDICAL COST OF GLAUCOMA IN SWEDEN
Ström O 1 , Buchholz P 2 , Walt JG 3 , Mesterton J 1 , Bengtsson B 4 , Heijl A 4 1 i3 Innovus, Stockholm, Uppland, Sweden, 2 Allergan Europe, Ettlingen, Germany, 3 Allergan Inc, Irvine, CA, USA, 4 Malmo University Hospital, Malmo, Sweden OBJECTIVE: Glaucoma has been estimated to affect 2.1% of the population aged 40 years and over and given the clinical impact of glaucoma, it is important to evaluate the potential economic burden of the disease. The aims were to estimate the direct medical costs of glaucoma in Sweden and also to investigate the hypothesized cost drivers; intraocular pressure (IOP), amount of visual field damage estimated by the MD, change of MD (ÄMD) and pseudoexfoliation syndrome (PEX). METHODS: The study was based on 583 Swedish patients with open-angle glaucoma and manifest field loss followed between 4.5 and 9.25 years. Data on MD, IOP, PEX, medical resources, and low-vision centre visits were collected and organized in three-month periods. The average baseline MD was -11.7 dB and initial values of average IOP, age were 22.5 mmHg, and 71 years, respectively. All used resources were multiplied with its respective unit costs to calculate the medical costs for each patient. Cost regressions were estimated with a multivariate population-averaged panel data model. RESULTS: Average annual medical cost/patient of glau-Abstracts A285
